Oppenheimer Holdings Inc. OPY

Key data

The business

Oppenheimer does two things. It runs a private-client business, financial advisors managing money for well-off households, which throws off fees on assets and commissions on activity. And it runs a capital-markets business: bankers who help midsize companies issue stock and bonds and do mergers, plus institutional desks in equities and fixed income. Wrapped around both is a growing river of interest income. The firm holds clients' cash and lends against their portfolios, and when short rates are high the spread on those balances is real money. Gross interest income ran about $64 million in the latest quarter alone, and the cost of that funding rose from $9.9 million for all of 2021 to $88.6 million in 2025 as rates climbed.

The moat is modest, and it is the advisor relationships: a household that has banked with the same advisor for fifteen years does not move for a basis point. The banking-and-markets side has no moat at all. It is a share-taker in a cyclical business the bulge brackets dominate. What you own is a well-run, family-controlled boutique that lives and dies by two cycles, the market's appetite for deals and the level of interest rates.

The numbers

The shape to see is a cyclical firm at or near the top of its cycle. Revenue climbed every one of the last four years off the 2022 trough, and 2025 set a record. The earnings line tells the truer story: $11.70 a share in the 2021 boom, collapsing to $2.57 and $2.59 in the 2022 to 2023 bust, then recovering to $6.37 and a record $13.04 in 2025.

The quarters explain why the record year deserves an asterisk, and why one of them turned red. The fourth quarter of 2025 alone earned $6.51, then the first quarter of 2026 swung to a $20.6 million loss. That loss is mostly an accounting mirage. As Oppenheimer's own shares surged toward $122, the liability it owes employees under stock-appreciation rights ballooned, and the mark against it drove GAAP negative even as the operating business earned an adjusted $4.21. A rising share price mechanically dents reported profit here, which is the opposite of how most firms read.

Which is the crux of the valuation, and two forces pull the real number apart. Trailing GAAP earnings of $8.86 put the stock at about 14 times, and the earlier read on this name asked only that earnings hold above $8. They did, at $8.86, through the first-quarter loss, and the dividend inched up to $1.76. On the company's adjusted basis, stripping the rights mark, the first half earned about $8.19, and a full-year figure near $16 would put the stock closer to 8 times, cheap. Against that, GAAP $8.86 leans on a peak capital-markets quarter and a peak-rate interest windfall, and mid-cycle earnings power sits closer to $6 or $7, or nearer 18 to 20 times. The honest anchor through both is book value, $93 a share, against which the stock trades at 1.34 times, a genuine re-rating for a firm that changed hands below book as recently as last year. What the market is not fully weighing, in my read, is how much of the recovery is rate-driven rather than franchise-driven. The interest windfall is not a moat, it is a gift from the Fed, and it reverses when rates do.

Management

Family-controlled, and mostly good hands. A.G. Lowenthal is executive chairman and Robert S. Lowenthal runs the firm as CEO, and the family's own money rides beside minority holders. The buyback record is the tell of an owner-operator who knows the cycle. Oppenheimer repurchased $60.6 million of stock in 2022 and $35.1 million in 2023 at average prices near $37 to $40, then all but stopped, buying just $3.0 million in 2025 as the price crossed $67. Buying hard when it was cheap and holstering when it was not is the reverse of how most managements behave, and it shrank the diluted share count about 9% in three years. Pay runs about 6% of net income and leans on incentive plans. The one insider transaction in the last year was a single $424,000 sale, immaterial. Dividends are a small part of the story at $1.76 a share, an 18% payout with room to grow.

How it fails or surprises you

Rate cuts drain the interest windfall. Net interest ran about $44 million a quarter, roughly $176 million annualized, and the funding cost behind it rose ninefold since 2021 as rates climbed. That line is a direct function of short rates on client cash and margin balances. A sustained Fed easing cycle pulls the spread back toward its zero-rate level and takes a large, high-margin slice of pretax income with it. Watch the quarterly net-interest sequence, which turns before earnings do.

Reported earnings are geared backward to the share price. The rights mark that produced the first-quarter loss cuts both ways: a falling stock would hand GAAP earnings a windfall while the business itself weakens. So the number the story explains least, a record operating year printing a loss quarter, is also the one most likely to mislead in reverse next time. Watch adjusted versus GAAP EPS side by side, not either alone.

Investment banking re-accelerates (right tail). Banking is where the operating leverage lives, with incremental deal fees falling to the bottom line at high margins. A durable mergers-and-underwriting cycle, layered on continued buybacks at owner-operator hands, could hold earnings near the 2025 $13 and keep return on equity in double digits, re-rating a stock the market spent a decade valuing below book. Watch investment-banking revenue year over year and book value per share.

Closing thoughts

The distribution here is no longer the fat pitch it was near the lows. The stock has roughly doubled off its 52-week low of $63.81 and sits at $122.89, a stone's throw from its high, at 1.34 times a slowly growing book. The left tail is a rate-cut cycle and a cooling deal market reverting normalized earnings toward $6 or $7 while the accounting swings against a still-high share price, at which point today's price is 18 to 20 times, not 14. The right tail is a sustained banking cycle and an owner-operator compounding book and count. I read the fatter tail as the downside from here, not because the firm is weak but because the easy re-rating below book is already spent, and two of its tailwinds, high rates and a hot capital-markets tape, are the parts most prone to mean-revert.

The bet, restated, is that Oppenheimer keeps earning more from managing wealthy families' money and helping midsize companies raise cash and do deals, and that the interest on client cash keeps flowing. What breaks it is rates falling and deal flow cooling at the same time, and the one pair of numbers that tells you first is the quarterly net-interest line against investment-banking revenue. If those two roll over together while the stock still trades above book, the record year of 2025 will read as the top, not the base.